Lv7
4730 积分 2021-07-21 加入
Complement biomarkers during iptacopan treatment
7天前
已关闭
Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial
23天前
已关闭
Recent Advances in Extended Half-Life Products, Nonfactor Replacement Therapies, and Gene Therpy for the Treatment of Hemophilia
24天前
已完结
Expanding the Toolbox With Non‐Factor Therapies
24天前
已关闭
RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT
27天前
已完结
Educational Strategies for Clinical Supervision of Artificial Intelligence Use
1个月前
已完结
Application of CMV‐IVIg as prophylaxis against cytomegalovirus reactivation in allogeneic hematopoietic stem cell transplantation patients
3个月前
已完结
CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma: lessons learned from clinical trials and real world evidence
3个月前
已完结
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
6个月前
已完结
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial
6个月前
已完结
皖公网安备34019202002308
